XTL Biopharmaceuticals Lt... (XTLB)
1.13
-0.03 (-2.59%)
At close: Apr 17, 2025, 2:23 PM
1.16
2.85%
After-hours: Apr 17, 2025, 02:23 PM EDT
-2.59% (1D)
| Bid | 0.85 |
| Market Cap | 9.96M |
| Revenue (ttm) | 162K |
| Net Income (ttm) | -772.28K |
| EPS (ttm) | -0.2 |
| PE Ratio (ttm) | -5.65 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 1.27 |
| Volume | 3,483 |
| Avg. Volume (20D) | 5,269 |
| Open | 1.10 |
| Previous Close | 1.16 |
| Day's Range | 1.10 - 1.13 |
| 52-Week Range | 0.92 - 3.15 |
| Beta | 1.01 |
About XTLB
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCD...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 1, 2005
Employees 8
Stock Exchange NASDAQ
Ticker Symbol XTLB
Website https://www.xtlbio.com